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Abstract
Summary This paper demonstrates a large post-fracture anti-osteoporosis treatment gap in the period 2005 to 2015. The gap was
stable in Denmark at around 88–90%, increased in Catalonia from 80 to 88%, and started to increase in the UK towards the end of
our study. Improved post-fracture care is needed.
Introduction Patients experiencing a fragility fracture are at high risk of subsequent fractures, particularly within the first 2 years
after the fracture. Previous studies have demonstrated that only a small proportion of fracture patients initiate therapy with an anti-
osteoporotic medication (AOM), despite the proven fracture risk reduction of such therapies. The aim of this paper is to evaluate
the changes in this post-fracture treatment gap across three different countries from 2005 to 2015.
Methods This analysis, which is part of a multinational cohort study, included men and women, aged 50 years or older,
sustaining a first incident fragility fracture. Using routinely collected patient data from three administrative health databases
covering Catalonia, Denmark, and the United Kingdom, we estimated the treatment gap as the proportion of patients not treated
with AOM within 1 year of their first incident fracture.
Results A total of 648,369 fracture patients were included. Mean age 70.2–78.9 years; 22.2–31.7% were men. In Denmark, the
treatment gap was stable at approximately 88–90% throughout the 2005 to 2015 time period. In Catalonia, the treatment gap
increased from 80 to 88%. In the UK, an initially decreasing treatment gap—though never smaller than 63%—was replaced by an
increasing gap towards the end of our study. The gap was more pronounced in men than in women.
Conclusion Despite repeated calls for improved secondary fracture prevention, an unacceptably large treatment gap remains, with
time trends indicating that the problem may be getting worse in recent years.
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Introduction
Osteoporosis is defined by microarchitectural changes of the
bone and reduced bone mass, causing an increased bone fra-
gility and an increased risk of fractures. Low-energy fragility
fractures are the clinical consequence of osteoporosis. In
2010, 27.6 million women and men in the European Union
were estimated to have osteoporosis, equivalent to a preva-
lence of 5.5% of the population. In the same year, a total of 3.5
million fragility fractures were sustained. Of these, 600,000
were hip fractures, 500,000 were clinical vertebral fractures,
600,000were forearm fractures, and 1.8million fractures were
categorized as “other” [1].
The presence of fragility fractures, irrespective of fracture
location, has been demonstrated to be indicative of a doubling
of the risk of a subsequent fracture [2, 3]. Depending on the
location of this initial fracture, a relative risk of subsequent
fractures of 1.4 to 19.0 as compared with those without frac-
tures has been demonstrated in prior studies [2]. The risk of
subsequent fractures is highest in the first 2 years after a frac-
ture, then decreasing over time [4]. Therapy with anti-
osteoporosis medications (AOM) is effective in preventing
subsequent fragility fractures. Accordingly, three Cochrane
reviews have confirmed the effectiveness of oral
bisphosphonates in secondary prevention of osteoporotic frac-
tures in general [5–7]. In addition, clinical trials in patients
with an osteoporotic fracture have demonstrated the signifi-
cant risk reduction of subsequent fractures with other AOM,
including zoledronic acid, denosumab, teriparatide, raloxi-
fene, and strontium ranelate [8–13]. In line with these find-
ings, national and international guidelines recommend either
assessment of osteoporosis or initiation of pharmacological
secondary fracture prevention—depending on guideline and
fracture location—in patients who sustain a fragility fracture,
unless exceptional circumstances exist [14–18].
Despite such evidence-based recommendations, a signifi-
cant post-fracture treatment gap is known to prevail across
healthcare systems and settings [19–28]. Several publications
report that in some countries as few as 10–20% of patients
with fragility fractures go on to receive AOM [23–27], with
this gap being more pronounced in men as well as in the
elderly [20, 26, 29]. Despite the attention given to the impor-
tance of closing the treatment gap, long-term time trends seem
to indicate that the gap has even been increasing in recent
years [25, 26].
Because the treatment gap is strongly affected by changing
healthcare resources and medical practices, comparative and
longitudinal time series analyses are needed to monitor sec-
ondary fracture prevention and to understand how structural
healthcare changes may affect this. However, few analyses are
long-term, and most often they present only a national per-
spective. The aim of this paper is to evaluate the changes in the
anti-osteoporosis treatment gap in secondary fracture
prevention in Denmark, the UK, and Catalonia from 2005
(2007 for the latter) to 2015.
Methods
This analysis forms part of the Multinational Observational
Database Study on Imminent Osteoporotic Fracture Risk
(the IFRISK study), an observational cohort study evaluating
patient characteristics and 1- and 2-year fracture rates in pa-
tients at high risk of osteoporotic fractures. This ongoing study
uses routinely collected health data obtained from three
European administrative health databases. The present work
is a cohort analysis of patients with a first incident osteoporot-
ic fracture in order to examine the changes in the anti-
osteoporosis treatment gap in the three countries from 2005
to 2015. The osteoporosis treatment gap is defined as the
proportion of patients not treated with AOM within 1 year
following their index fracture.
Population
Eligible patients were men and women, aged 50 years or
older, with a first incident (= index) fracture at any site except
face, skull, and digits, as fractures at these sites are generally
considered non-osteoporotic. If within the 6 months prior to
the incident fracture, a fracture had been coded at the same
anatomical site as the incident fracture, the incident fracture
would be considered a repeat admission for the original frac-
ture rather than a first fracture. Patients had to be registered in
one of the national health registries at least 1 year prior to their
index fracture. We pre-specified exclusion of patients with
Paget’s disease, a history of breast or prostate cancer, or a
history of bone metastasis. Additionally, CPRD and SIDIAP
general practices with a lack of linkage to hospital admissions/
records were excluded to maximize the quality and complete-
ness of the analytical dataset.
Data sources
We extracted patient-level data on the index fracture along
with baseline demographic, clinical, socioeconomic, andmed-
ication information from the following registries:
& Clinical Practice Research Datalink (CPRD) GOLD,
which comprises data from primary care linked to hospital
and outpatient data (secondary care), including data on
demography and medication, from over 7 million patients
in the UK.
& Sistema d’Informació per al Desenvolupament de la
Investigació en Atenció Primària (SIDIAP), which repre-
sents more than 6 million people in Catalonia (Spain) and
is based on primary care records linked to pharmacy
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dispensations and hospital inpatient data. Data from
SIDIAP is available from 1st January 2006, a date consid-
ered of standard and established use of electronic medical
records in Catalonia.
& Danish Health Registries (DHR), including the National
Prescriptions Database (which contains data on all filled
prescriptions since 1995), the National Patient Registry
(which contains diagnosis codes and treatments for all
patients since 1977 for hospitals and since 1995 for out-
patient clinics), and the National Cause of Death register
(which includes date and cause(s) of death). These regis-
ters cover the entire Danish population until death or
emigration.
Study period
Baseline was defined as the date of the index fracture. The
baseline period (i.e. the lookback or “window” period) to
identify baseline demographic, clinical, and socioeconomic
characteristics was defined as the 12 months leading up to
the index fracture. The exception was medical history (cancer,
cardiovascular disease, diabetes, arthritis, liver disease, de-
mentia, neurological conditions, asthma or chronic obstructive
pulmonary disease, chronic kidney disease, endocrine disease,
and malabsorption), for which no limitations in the length of
the lookback period was applied.
Follow-up data included treatment withAOMwithin 1 year
of the index fracture, defined as any use of bisphosphonates,
teriparatide, denosumab, strontium ranelate, or raloxifene. For
SIDIAP and DHR, treatment was characterized by pharmacy
dispensation of AOM, while for the CPRD, it was character-
ized by AOM prescription. These differences were due to the
content of the data sources. Data was collected for patients
with an index fracture between 2005 (2007 for SIDIAP) and
2015.
The study protocol was approved by the ISAC ethics com-
mittee for use of CPRD data, by the SIDIAP Scientific and
Ethics Committee, and for the use of the Danish Health
Registries by the Danish Medicines Agency, the Danish
Data Protection Agency, and Statistics Denmark.
Statistical analysis
The three databases were curated using a bespoke (protocol-
based) common data model and code lists. A single script
(written in R version 3.3.2) was used for the analysis, which
was run independently on each database. For each database,
we summarized the baseline characteristics (both demograph-
ic and clinical) descriptively. Continuous variables were sum-
marized using mean and standard deviation, while categorical
variables were summarized by the number and/or proportion
of participants.
Data was censored at the first occurrence after the index
date of either an additional osteoporotic fracture, death or
migration, or 1 year after the date of the index fracture. All
analyses were stratified according to fracture location and year
of fracture. In an additional analysis, we further stratified the
data according to gender. In the presentation of the data, we
pooled the data into 4 distinct time periods for smoothening
(2005–07, 2008–10, 2011–13, and 2014–15, respectively).
Results
A total of 1,282,991 patients were eligible for the study. After
the pre-specified exclusion of patients less than 50 years old at
the time of the index fracture (n = 602,167), those with an
index date after 31st December 2015 (n = 7862), those with
a history of Paget’s disease (n = 358), breast or prostate cancer
(n = 23,668), and/or bone metastasis (n = 691),1 a total of
648,369 fracture patients were included in this study. Of these,
83,514 were recorded in CPRD (UK), 55,304 in SIDIAP
(Catalonia), and 509,551 in DHR (Denmark). Table 1 shows
the baseline characteristics of each of these sub-cohorts. At
baseline, the groups differed significantly on several charac-
teristics. Notably, the participants from the UK were older
(mean age 78.9 years), one in five was male, and more had a
history of cancer (8.9%) or chronic kidney disease (11.9%). In
comparison, the Danish cohort were younger (mean age
70.8 years), one in three was male, and they had the lowest
Charlson Comorbidity Index (CCI) score (86.4% had a CCI of
0). The Catalan cohort were relatively comparable with the
Danish, yet had the highest CCI score (> 26% had a CCI of
2 or more), also exceeding that of the UK population.
Interestingly, the number of participants on steroids in the past
year was comparable between the three countries, irrespective
of the differences in age and CCI score. Prevalent use of anti-
osteoporosis medication at baseline was highest in Catalonia
(10.3%) followed by the UK (9.2%), while the use in
Denmark was substantially lower (4.8%).
Treatment gap: general trend
Figure 1 shows the treatment gap across all fracture loca-
tions for the UK, Catalonia, and Denmark from 2005 to
2015 (Catalonia from 2007). The treatment gap was largest
in Denmark, and remained stable over the study period at
88–90%. In comparison, the treatment gap was lowest in
the UK at the starting point in 2005–07 and demonstrated a
decreasing trend during the two subsequent time periods.
In 2011–13, 37% of all patients aged 50 years or older and
presenting with a first fracture were treated with anti-
osteoporosis medication within 1 year (i.e. a treatment
1 Please note that groups are not mutually exclusive
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gap of 63%). In the last time period (2014–15), the treat-
ment gap in the UK increased again but still remained
lower than that seen in 2005–07. In Catalonia, the treat-
ment gap was at 80% in 2007 and has been increasing since
the 2008–10 time period and until the end of this study, at
which point it was around 88%. Overall, within each coun-
try, the trends for individual fracture sites were similar to
those seen for all fractures. Details regarding the treatment
Fig. 1 The treatment gap for all
fractures across the
United Kingdom, Catalonia and
Denmark. The treatment gap is
given as the proportion of patients
not treated with AOM within
1 year following their index
fracture
Table 1 Baseline characteristics
CPRD SIDIAP DHR
N 83,514 55,304 509,551
Age, years (mean (SD)) 78.9 (11.2) 70.2 (13.7) 70.8 (12.4)
Sex, male (%) 22.2 31.7 30.9
BMI; kg/m2 (mean (SD)) 25.0 (5.5) 28.9 (5.2) N/A
Medical history (%)
Cancer 8.9 5.9 7.0
COPD 5.8 5.9 5.3
IHD 2.8 N/A 4.2
CKD 11.9 7.3 1.2
Charlson comorbidity index (%)
0 59.2 48.5 86.4
1 18.1 24.9 7.9
2 10.8 13.3 3.6
3 6.4 6.8 1.1
≥ 4 5.5 6.5 1.1
Steroid use in previous year* (%) 7.8 8.2 8.3
PPI use in previous year (%) 23.0 48.9 14.5
Anti-osteoporosis medication in previous year† (%) 9.2 10.3 4.8
BMI bodymass index,CKD chronic kidney disease,COPD chronic obstructive pulmonary disease, IHD ischaemic heart disease,N/A not available, PPI
proton pump inhibitor
* Steroid use is defined as filled prescriptions of a glucocorticoid at a total dose equivalent to ≥ 450 mg prednisolone during the baseline period
†Anti-osteoporosis medication includes bisphosphonates, teriparatide, denosumab, raloxifene, and strontium ranelate and for SIDIAP also bazedoxifene
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gaps can be found in Figs. 1, 2, 3, 4, and 5 and supplemen-
tary Tables 1, 2, 3.
The United Kingdom
Figure 2 shows the treatment gap in the UK from 2005–07 to
2014–15, stratified according to fracture location. As de-
scribed above, the treatment gap diminished from 2005–07
to 2011–13 then started to increase again. As is seen in
Fig. 2, this was a general tendency across fracture locations.
Secondary prevention among hip fracture patients was better
than average throughout the study period.
Catalonia
As demonstrated in Fig. 3, the treatment gap in Catalonia
increased from the 2008–10 time period and throughout the
study across all fracture locations. Like in the UK, the second-
ary prevention among hip fracture patients was marginally
better than average. Interestingly, secondary prevention
among patients with spine fractures was remarkably better,
yet the treatment gap still increased over time.
Denmark
The treatment gap in Denmark was stable throughout the
study period, as is seen in Fig. 4. This was remarkably similar
across fracture locations, with only minor deviations across
the time periods. As in Catalonia, the treatment gap among
hip fracture patients was smaller than average yet even smaller
for spine fracture patients. The treatment gap among patients
with spine fractures demonstrated an increasing trend towards
the end of this study.
Treatment gap: gender discrepancies
Figure 5 demonstrates the treatment gap across the three da-
tabases stratified according to gender for all, hip, and spine
fractures, respectively. Across the UK, Catalonia, and
Denmark, a similar trend of a larger treatment gap in men than
in women was observed, irrespective of fracture location. The
trend for non hip, non spine fractures and wrist fractures was
similar (data on file). We did not observe any consistent
changes in the gender difference over the years.
Discussion
This analysis shows the presence of very significant treatment
gaps in the secondary fracture prevention across three
European countries but with some differences between the
countries. In the UK, the treatment gap was 63–73% during
the study period; in Catalonia, it was 80–88%; and in
Denmark, it was stable at 88–90%. Although the UK exhibit-
ed a narrowing treatment gap in the first years of our analysis,
as well as an overall reduction in the treatment gap from 2005
to 2015, a trend towards an increase is noted towards the end
of the study period. In Denmark, the gap was large and stable
during the analysis, and in Catalonia, the treatment gap
showed an increasing overall trend since the 2008–10 time
period. Across the three countries, the treatment gap was con-
sistently larger in men than in women.
The results of our analysis are in line with other studies on
secondary fracture prevention, which have demonstrated sig-
nificant treatment gaps across healthcare systems and settings
[19–26, 28, 30]. While many such studies are based in North
America [19–22, 25, 26, 28], our study along with several
Fig. 2 The treatment gap in the
United Kingdom stratified
according to fracture location (all,
hip, spine, non hip non spine, and
wrist fractures, respectively) and
time period
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others demonstrate that the treatment gap seems to be a uni-
versal problem [23, 24, 30], also pertaining to European
healthcare systems with a high level of access. Previous lon-
gitudinal studies have demonstrated an increasing treatment
gap over time [25, 26], and while our study provides more
recent data with significant differences between the UK,
Catalonia, and Denmark, the overall impression is that the
gap is stable or increasing in recent years. Hence, despite
repeated calls for improved secondary fracture prevention on
an international scale and improved availability of AOM—
including the emergence of new osteoporosis drugs with
new characteristics that could widen patient acceptance of
AOM as well as the availability of generic AOM—we have
yet to see signs that this is improving. It deserves mentioning
that a genera l t rend towards a decl in ing use of
bisphosphonates, which has coincided with reports of rare or
very rare adverse events as demonstrated by Jha et al. (2015),
may contribute to the increasing treatment gap and hence
wash out some of the effect of initiatives to improve secondary
fracture prevention [31, 32]. This trend was observed despite
the fact that the absolute risk of such deleterious adverse
events, notably atypical femur fractures, and osteonecrosis
of the jaw, is very low [32, 33]. Further, the International
Osteoporosis Foundations Capture the Fracture programme
was launched in 2012, coinciding with the smallest treatment
gap in the UK in our analysis (during the 2011–13 time peri-
od), yet it is unlikely that our data reflects the full impact of a
programme that has been expanding significantly since then.
Fig. 3 The treatment gap in
Catalonia stratified according to
fracture location (all, hip, spine,
non hip non spine, and wrist
fractures, respectively) and time
period
Fig. 4 The treatment gap in
Denmark stratified according to
fracture location (all, hip, spine,
non hip non spine, and wrist
fractures, respectively) and time
period
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Our analysis demonstrated significant differences in sec-
ondary fracture prevention between the geographic areas cov-
ered, with the UK achieving a substantially smaller treatment
gap than Catalonia and, in particular, Denmark. As this study
is based on administrative health databases, these differences
may be reflective of underlying differences in data generation.
Hence, in Denmark and Catalonia, patients are counted as on-
treatment if they fill their prescriptions for AOM at the phar-
macy, while in the UK, the patients are counted as on-
treatment if they are prescribed an AOM. Patients with prima-
ry non-adherence would thus be counted in the CPRD as on
treatment, while they would count as untreated in Denmark
and Catalonia. This may cause an overestimation of the true
adherence to osteoporosis guidelines in the UK. For compar-
ison, a primary non-adherence rate of 20% has been calculated
in SIDIAP, which beyond pharmacy dispensation data also
holds prescription data like in the UK. Also, while the DHR
is based on hospital data, CPRD and SIDIAP are based on
primary care records linked to secondary care. This may ex-
plain some of the baseline differences, as primary care records
generally tend to be more granular with regards to medical
history as compared with secondary care records. Further,
we predefined exclusion of patients with a lack of linkage to
secondary care records, which has been suggested to account
for 40% of CPRD practices and 70% of SIDIAP practices.
This exclusion carries the risk of skewing the study population
and may add to the differences in the treatment gap observed
between the UK, Catalonia, and Denmark.
However, despite such potentially influencing factors, we
believe that the national differences are, at least in part, indic-
ative of more profound differences in secondary fracture pre-
vention. These could reflect differences in access to care,
yet all the countries in this study sustain a government-
funded national healthcare system (although in Catalonia,
co-payment policies was implemented in 2011, yet this does
not seem to further fuel the increasing treatment gap), and,
further, the Danish population did not appear to be significant-
ly more impaired than the Catalan or UK populations, yet still
demonstrated the poorest secondary fracture prevention.
Another reason for the differences between the countries
may be differences in national osteoporosis guidelines.
While guidelines today seem to agree on the relevance of
AOM therapy in patients with fragility fractures, as most re-
cently evidenced by the ASBMR clinical recommendations
(Conley et al., 2020) focusing on hip and vertebral fractures
in patients aged 65 years or older [14, 15, 18, 33], UK guide-
lines have historically been less reliant on DXA-scans for the
diagnosis of osteoporosis and thus for AOM treatment initia-
tion than Danish or Spanish guidelines. This may have facil-
itated a smaller treatment gap in the UK in the early years of
this analysis yet does not explain why the treatment gap per-
sists in Denmark and Catalonia in recent years and increases
towards the end of this study in the UK. We are not aware of
evidence of diminishing use of DXA-scans in these countries,
as has been demonstrated in the USA (coinciding with re-
duced reimbursement) [34].
Finally, differences in the healthcare system may affect the
size of the treatment gap, in particular the implementation of
care models for secondary prevention of fragility fractures. In
a literature review, Ganda et al. (2013) demonstrated that frac-
ture liaison services (FLS) are associated with significant im-
provements in BMD testing and treatment initiation in patients
who have sustained a fragility fracture [35]. They found that
increasing intensity of the FLS intervention was associated
Fig. 5 The treatment gap in the United Kingdom (a), Catalonia (b), and Denmark (c), stratified according to time period, gender, and fracture location
(all, hip, and spine, respectively)
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with greater effectiveness of the FLS and that the FLS is cost-
effective in daily clinical practice [35]. The UK began
implementing FLS services systematically a decade ago.
More recently, an FLS database for England and Wales was
established under the auspices of the Royal College of
Physicians, and this has captured data in real time since
January 2016. It has been reported that in 2017, 43% of all
fragility fractures were submitted to an FLS service [36]. Of
these, 70% were assessed within 90 days of their fracture, and
43% were recommended AOM treatment initiation [36].
Catalonia now has a relatively high number of accredited
FLS services according to the IOF “Capture the Fracture”
Map of Best Practice (www.capturethefracture.org) yet is still
less comprehensively covered than the UK. Despite these re-
ports being more recent than the study period covered in this
paper, they point towards a higher level of attention towards
secondary fracture prevention in Catalonia and, particularly,
the UK. By contrast, fracture liaison services had not been
systematically implemented in Denmark within the study pe-
riod, and only three Danish hospitals now run an IOF
“Capture the Fracture” accredited programme. This failure to
provide follow-up services for fracture patients may contrib-
ute to the differences in the treatment gap observed between
the three countries in this analysis.
An important aspect that needs to be kept in mind is that a
100% treatment rate would not necessarily be indicative of
good clinical practice. Contraindications to the medications
certainly exist and the benefit from treatment depends on life
expectancy and the risk of side effects. In addition, patient
preferences may also limit the number of patients that can be
initiated on pharmacological therapy. To this end, the Royal
College of Physicians introduced an FLS key performance
indicator where 50% of patients should be initiated on phar-
macological therapy [36]. This could be too low a target and
benchmarking from secondary prevention in myocardial in-
farction; Leslie et al. (2012) argued that a pharmacological
intervention target of 80% of patients with hip or spine frac-
tures may in fact be more reasonable [37]. Irrespectively, the
treatment gaps across the countries evaluated in this analysis
are too large and require prompt addressing.
A limitation relevant to CPRD and SIDIAP is that we only
capture those patients registered in the database and linked to
hospital records. Both databases have been validated as rep-
resentative of the national/regional population, yet, as signif-
icant proportions of the patients in CPRD and SIDIAP were
excluded due to a lack of linkage to hospital records, there is a
risk that our results may not be representative of the general
population.
Another limitation is that use of zoledronic acid and
denosumab are not regularly reflected in CPRD for this time
period, while in Denmark hospital-administered zoledronic
acid is not reflected in the National Prescription Registry.
This may cause an underestimation of the treatment rate.
Our study has a number of strengths including the large
number of patients and fractures evaluated, the robustness of
the methodology, and the use of validated databases.
In conclusion, this study provides long-term, comparative
data regarding the treatment gap after an incident osteoporotic
fracture among patients from the UK, Catalonia, and
Denmark. We have demonstrated that despite repeated calls
for improved pharmacological secondary prevention, an un-
acceptably large treatment gap still exist, more pronounced in
men than in women. Differences in the treatment gap are
evident across the countries evaluated in our analysis, possibly
arguing in favour of the effectiveness of structural healthcare
interventions. Regardless, our study highlights that additional
efforts to reduce the treatment gap are highly and urgently
needed.
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